Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion
Author:
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Link
https://www.nature.com/articles/s41423-023-01048-3.pdf
Reference44 articles.
1. Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151–72. https://doi.org/10.1038/s41571-021-00573-2.
2. Makker V, Colombo N, Casado Herraez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus Pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386:437–48. https://doi.org/10.1056/NEJMoa2108330.
3. Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The tumor microenvironment: A Milieu hindering and obstructing antitumor immune responses. Front Immunol. 2020;11:940 https://doi.org/10.3389/fimmu.2020.00940.
4. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325–40. https://doi.org/10.1038/nrclinonc.2018.29.
5. Pottekat A, Menon AK. Subcellular localization and targeting of N-acetylglucosaminyl phosphatidylinositol de-N-acetylase, the second enzyme in the glycosylphosphatidylinositol biosynthetic pathway. J Biol Chem. 2004;279:15743–51. https://doi.org/10.1074/jbc.M313537200.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. CRISPR/Cas9 screening: unraveling cancer immunotherapy’s ‘Rosetta Stone’;Trends in Molecular Medicine;2024-08
2. CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects;Frontiers in Immunology;2024-07-18
3. CRISPR–Cas9 applications in T cells and adoptive T cell therapies;Cellular & Molecular Biology Letters;2024-04-12
4. Mechanism-directed combinational immunotherapies in liver cancer hold promise;Cellular & Molecular Immunology;2023-08-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3